Ilaris (Canakinumab)

What it is and what it treats

Ilaris (canakinumab) is a fully human monoclonal antibody that selectively binds and neutralises interleukin-1 beta (IL-1β), a key pro-inflammatory cytokine implicated in a group of rare autoinflammatory conditions collectively driven by dysregulated IL-1 signalling.

Approved indications described in regulatory labelling include Cryopyrin-Associated Periodic Syndromes (CAPS, including Familial Cold Autoinflammatory Syndrome and Muckle-Wells Syndrome), Systemic Juvenile Idiopathic Arthritis (SJIA), Adult-Onset Still's Disease, and periodic fever syndromes such as Familial Mediterranean Fever, TNF Receptor-Associated Periodic Syndrome and Hyperimmunoglobulin D Syndrome. In some regions Ilaris is also approved for frequent flares of gouty arthritis when standard therapies are unsuitable.

By blocking IL-1β signalling, canakinumab is described in clinical literature as reducing fever episodes, normalising acute-phase inflammatory markers such as CRP and serum amyloid A, and limiting the risk of long-term organ complications associated with chronic autoinflammation.

Presentations and dosage forms

• Powder for solution for injection, 150 mg per vial, for reconstitution
• Solution for injection in pre-filled formats in some markets
• Administered by subcutaneous route only

How it is administered

The EU SmPC describes dosing that varies by indication: for CAPS in adults and children above a defined body weight, a commonly described regimen is 150 mg every eight weeks; for Systemic Juvenile Idiopathic Arthritis, dosing is described on a body-weight basis, typically 4 mg/kg every four weeks; and for periodic fever syndromes, 150 mg every four weeks is described, with adjustments for lower body weights.

Ilaris is administered by subcutaneous injection following reconstitution of the lyophilised powder. Patients or caregivers may be trained to administer injections at home once appropriate education on technique and reaction recognition has been provided.

Before initiating therapy, screening for latent tuberculosis and other active infections is described in the label, given the immunomodulatory mechanism of action; ongoing monitoring for infection and, in SJIA patients, macrophage activation syndrome is advised throughout treatment.

Storage and handling

• Store at 2–8 °C under continuous refrigeration; do not freeze
• Keep the vial in the outer carton to protect from light
• Do not shake the vial during reconstitution
• Use reconstituted solution within the timeframe specified in the SmPC
• Cold-chain integrity must be maintained throughout transport and storage

Side effects

The following reflects the adverse reaction profile described in the approved EU SmPC for canakinumab.

Commonly reported

Serious effects requiring medical attention

Patients should seek prompt medical review if signs of infection, unexplained fever, bruising or bleeding occur; suspected adverse reactions should be reported through the relevant national pharmacovigilance scheme.

Ilaris compared with other IL-1-targeted therapies

Ilaris differs from anakinra, a daily-dosed IL-1 receptor antagonist that blocks both IL-1α and IL-1β, and from rilonacept, a weekly-dosed IL-1 trap. Canakinumab's selective targeting of IL-1β and long half-life allow for less frequent dosing intervals of four to eight weeks depending on indication.

The choice between IL-1-pathway therapies depends on the specific autoinflammatory diagnosis, approved indications in the relevant jurisdiction, and individual patient response, and should be made by a specialist experienced in autoinflammatory disease management.

Availability and supply route

Marketing authorisation status for Ilaris varies by country, and approved indications, dosing regimens and pack presentations may differ between the EU, US and other regulated markets. Clinicians and institutions should verify local registration status before planning treatment.

Where a specific indication or presentation is not registered locally, named-patient or specials import mechanisms exist in many jurisdictions to permit supply of a foreign-registered medicine against a valid prescription and appropriate regulatory documentation.

Pharmacy Remedy is a licensed Turkish pharmaceutical wholesaler that supplies medicines through licensed distribution channels to hospitals, pharmacies and other authorised institutions; it does not sell medicines directly to the public and all supply is conditional on valid prescriptions and applicable import documentation.

Frequently asked questions

Primary sources

• EMA EPAR — Ilaris
• FDA prescribing information — Ilaris

Further reading and regulatory routes

• How to verify a medicine is genuine
• Why medicines cost less in Türkiye
• WHO falsified medicine alerts
• Named patient supply
• UAE import guide
• For healthcare professionals
• All medicine monographs

Related medicines

• Cerezyme (imiglucerase)
• Fabrazyme (agalsidase beta)
• Keytruda (pembrolizumab)